Cereno Scientific publishes prospectus in connection with rights issue of units of approximately SEK 110 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Cereno Scientific AB (publ) (“Cereno Scientific” or the “Company”) has prepared an EU growth prospectus (the “Prospectus”) for the forthcoming issue of units consisting of shares and
Intervacc AB (publ) has held its Extraordinary General Meeting (”EGM”) on Friday 5 May 2023, at which a resolution on authorisation for the board of directors to resolve on rights issue of shares was made
The EGM authorised the board of directors to, in the period until the next annual general meeting, resolve on a new issue of shares with preferential rights for the company's shareholders. The total number of shares that may be issued based on the authorisation must be within the limits of the share capital according to the articles of association and may not exceed such number of
